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INTRODUCTION
We proposed that subtle variation in the expression or function of genes expressed as a consequence of interactions between ovarian cancer cells and the host microenvironment could contribute to susceptibility to ovarian cancer. This idea was novel because this class of genes has not previously been tested for a role in ovarian cancer susceptibility. Our approach, and our choice of candidate genes, was based on extensive preliminary data we have accumulated from co-culture of fibroblast and epithelial ovarian cells. Our original aim was to identify all non-synonymous coding and putative promoter SNPs in 60 candidate genes highlighted by our analysis of cross talk between fibroblast and epithelial elements of ovarian tumors, as well as a set of tagging SNPs in 20 of these co-culture regulated genes which are altered in expression in serous tumours, compared with normal ovarian surface epithelial cells. However, at the start of this project we acquired an Illumina Bead Station and so we genotyped 1536 SNPs in the first stage, allowing us to genotype potentially functional as well as tagging SNPs in 174 genes of interest in 773 cases with invasive, serous ovarian adenocarcinoma, and 1365 controls. This task was followed by independent 'validation' of the most significant associations in up to 7,139 cases and 7,851 controls. None of these SNPs showed significant associations with ovarian cancer risk in pooled analysis, adjusted for study and age, under any model.
BODY
The statement of work was altered in December 2006 because we changed genotyping platforms in order to genotype many more SNPs, but with an altered the time frame. The tasks below are from the new SOW.
Task 1. In silico identification of SNPs in candidate genes (months 1-9)

identification of 174 candidate genes involved in cross talk
The original application proposed genotyping of candidate genes based on a series of in vitro experiments involving co-culture of ovarian epithelial and theca fibroblast cells. The genes were further prioritized based on elevated expression in two published ovarian cancer expression profiling studies, as well as an in house expression profile and we then generated a list of 255 candidate genes of interest.
identification of 1536 tagging SNPs, nsSNPs and SNPs in putative microRNA binding sites in these 174 genes
With Drs Ellen Goode and David Rider at the Mayo Clinic, and Illumina Inc., we then generated a list of SNPs within 5 kb of these 255 genes (58,114 SNPs in total). We then used the binning algorithm of LDSelect to identify 4567 tagSNPs among these, with (r2) > 0.8 and minor allele frequencies (MAFs) > 0.05, using data from a variety of sources. Then we prioritized the list to 166 genes based on known function and the number of bins in each gene (excluding genes with a large number of bins), in an attempt to reduce the list to ~1500 SNPs.
We then requested from Illumina Inc the design scores for all SNPs within 5kb of these 166 genes and picked the best tagSNP in each bin (or two tagSNPs if there are >10 tagging SNPs in a bin and none had an optimal design score).We also used www. While the design of the Illumina OPA was underway we completed the extraction and Quality Control of 1350 case and 1100 controls DNAs from the Australian Ovarian Cancer Study (AOCS), and the making of plates for Goldengate genotyping using cases and controls from both the AOCS and the Australian Cancer Study.
We have now genotyped 2138 samples for 1536 SNPs in 174 genes. There were 773 invasive serous cases from the Australian Ovarian Cancer Study (527), Australian Cancer Study (121) and Mayo Clinic (125), with 1365 controls from the same sources (893, 411 and 61 respectively). Insufficient DNA was available from the AOCS to achieve our original aim of genotyping 900 invasive serous cases, but additional power was obtained by using a larger number of controls.
Plates were prepared containing randomly mixed cases and controls, with two duplicated samples and one blank per plate. The Golden Gate assay was performed according to the manufacturer's instructions. Following completion of the assay for all 23 plates, analysis was carried out using Illumina BeadStudio software version 3.1.0.0. The following quality control measures were implemented:
The original raw dataset contained genotype information for 2208 samples and 1536 SNPs. Following automatic clustering, SNPs were ranked using their "GenTrain" score, number between 0 and 1 indicating how well the samples clustered for this locus. SNPs with a low score were checked manually and re-clustered if possible. Subsequently all SNPs were checked for clustering quality.
Next, SNPs were filtered based on call rate with a call rate > 95% deemed as acceptable. Additional filter steps included removal of SNPs with a minor allele frequency of zero. Hardy Weinberg equilibrium was also tested for each SNP, and only those that passed a low threshold, with a p value > 0.0001, were included. SNPs with two or more discrepancies between duplicate pairs were excluded.
For sample quality control, a call rate threshold of 95% was used so that samples that failed for >95% SNPs were excluded which reduced the number of samples from 2208 to 2145. Analysis of signal intensities across all plates revealed three plates (#16-18) with low intensity, just prior to the annual service of the laser. A separate analysis looking at call rates and concordance for each plate showed that these same plates failed quality control thresholds ( Figure 1 ) and so they were omitted from further analysis. 
PLATE # SNPs with CF <95%
The final dataset therefore comprised 1839 samples (675 cases and 1164 controls) with genotype information for 1292 SNPs in 174 genes. An analysis using the PLINK software package was then performed. The following exclusion criteria were applied: SNPs with at least one failed duplicate, SNPs with a significantly different proportion of missing genotype data between cases and controls (P Miss <0.05), SNPs not conforming to HW proportions (P HWE <0.05) for either cases, controls or both, and SNPs with no significant trend in allelic dose response (P Trend >0.05). From this list, we further estimated which SNPs are likely to be the best predictors of ovarian cancer (PPV) according to the p-values derived from the most robust test for allelic association i.e P Trend , the power of the study to detect this association, and the prior probability of 0.0001. We selected SNPs for validation in Task 4 from this list.
Based on their Positive Predictive Values, the Ovarian Cancer Association Consortium decided to genotype three of these SNPs in PODXL, ITGA6 and MMP3. In addition, the three SNPs in PODXL (rs1013368), ITGA6 (rs13027811) and MMP3 (rs522616) were genotyped in 7,139 cases and 7,851 controls from 12 sites in OCAC.
statistical analysis
None of these 25 SNPs showed significant associations with ovarian cancer risk (P > 0.03) in pooled analysis, adjusted for study and age, under any model. The per allele adjusted OR for rs1013368 was 0.99 (95% CI 0.90-1.09), for rs13027811 was 0.97 (95% CI 0.85-1.09) and for rs522616 was 1.06 (95% CI 0.98-1.16).
In addition, we combined our data on 18 SNPs in FGF2 (some of which showed a nominal association with ovarian cancer risk) with that of three other sites in OCAC from the United States who had genotyped 17 of these, and 7 additional ones. Analysis was restricted to non-Hispanic White women with serous ovarian carcinoma (1269 cases and 2829 controls). There were two nominally statistically significant associations between heterozygosity for two FGF2 SNPs (rs308379 and rs308447; p<0.05) and serous ovarian cancer risk in the combined dataset, but rare homozygous estimates did not achieve statistical significance, nor were they consistent with the log additive model of inheritance. Overall genetic variation in FGF2 does not appear to play a role in susceptibility to ovarian cancer.
Task 5. DHPLC to identify putative functional SNPs in genes associated with serous invasive ovarian cancer in both the test and replication set (months 25-35)
design of DHPLC primers 2. DHPLC of coding and conserved regulatory regions of ~5 genes in 94 moderate familial risk ovarian cancer cases
This task was not longer appropriate given the failure to validate our results in OCAC.
Task 6. Functional evaluation of putative rSNPs (months 28-36)
This task therefore was not undertaken.
Task 7. Manuscript preparation (months 32-)
The main manuscript is currently in preparation. In addition, we have submitted one on the analysis of SNPs in FGF2.
KEY RESEARCH ACCOMPLISHMENTS
We 
CONCLUSION
Although the results of this study have been disappointingly negative, they highlight the importance of consortium-based approaches to investigate putative ovarian cancer genetic associations given the need for large sample sizes. Without the ability to validate our 'positive' findings (most of which were of borderline significance) in OCAC, we would have published false-positive results, adding to the already flawed literature in this area. These data will complement those from Genome Wide Association Studies which do tag all genes with the same depth as we have for these 174 candidate genes. 
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transformation of epithelial cells. We therefore hypothesized that subtle variation in the expression or function of genes expressed as a consequence of interactions between ovarian cancer cells and the host micro-environment, and in genes differentially expressed in normal ovarian surface epithelial (OSE) cells compared with inclusion cysts (IC) and invasive serous ovarian tumours, could contribute to susceptibility to invasive serous ovarian cancer. Based on extensive preliminary data from co-culture of fibroblast and epithelial ovarian cells, we identified 1,536 tagSNPs, miRNA binding site SNPs and nonsynonymous SNPs with minor allele frequencies (MAFs) > 0.05, from 174 candidate genes expressed in serous ovarian tumours as a result of cross talk between ovarian epithelial and stromal cells, of which a subset were also known to be differentially expressed between OSE cells and ICs/tumours. These were genotyped with the Illumina GoldenGate Assay™, and after quality control checks our final dataset consisted of 1282 SNPs genotyped in 675 invasive serous cases and 1164 controls from the Australian Ovarian Cancer Study, Australian Cancer Study and the Mayo Clinic. The risk of ovarian cancer associated with the minor allele for each SNP was estimated from a basic allelic association test for each SNP, as well as the Cochran-Armitage trend test.
The best predictors of ovarian cancer risk were SNPs in PODXL, ITGA6 and MMP3. tgSNPs that had failed QC in these three genes were then genotyped by iPLEX, before SNPs were selected for validation. Three SNPs in PODXL, ITGA6 and MMP3 which had Positive Predictive Values of 33%, 4.5% and 4.1% respectively are currently being analysed in the whole of the Ovarian Cancer Association Consortium, as well as a further 19 SNPs in PTTG1, CSF1, PLOD2, FGF2, TIMP3, DDR2, FN1, MMP7, PANX1, PTEN, ITGAV and LCN2 in a subset of OCAC studies (SEARCH, MALOVA, UKOPS and USC). Results of these validation studies will be presented.
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Statement on novelty and impact of this study
This is the first study to assess the association between tagging SNPs in the FGF2 gene and serous ovarian cancer in a large study of US and Australian women. Our study showed no significant association between any of the 25 FGF2 SNPs analyzed and risk of serous tumors among non-Hispanic White women, and highlights the value of large international consortia to thoroughly evaluate candidate susceptibility genes.
Abstract
Fibroblast growth factor (FGF)-2 (basic) is a potent angiogenic molecule involved in tumor progression, and is one of several growth factors with a central role in ovarian carcinogenesis. We hypothesised that common single nucleotide polymorphisms (SNPs) in the FGF2 gene may alter angiogenic potential and thereby susceptibility to ovarian cancer. We analysed 25 FGF2 tgSNPs using five independent study populations from the United States and Australia. Analysis was restricted to nonHispanic White women with serous ovarian carcinoma (1269 cases and 2829 controls). There were no statistically significant associations between any FGF2 SNPs and ovarian cancer risk. There were two nominally statistically significant associations between heterozygosity for two FGF2 SNPs (rs308379 and rs308447; p<0.05) and serous ovarian cancer risk in the combined dataset, but rare homozygous estimates did not achieve statistical significance, nor were they consistent with the log additive model of inheritance. Overall genetic variation in FGF2 does not appear to play a role in susceptibility to ovarian cancer. These results highlight the importance of consortium-based approaches to investigate putative ovarian cancer genetic associations given the need for large sample sizes.
Introduction
Ovarian cancer is the seventh leading cause of cancer mortality among women globally, accounting for 4.2% of cancer deaths 1 . Lethality of ovarian cancer is due in part to the absence of symptoms in the majority of cases who typically present with metastatic disease that has spread outside the pelvis 2 . The lack of practical screening methods and detectable symptoms in the early stages of tumor progression underscore the importance of a better understanding of the molecular aspects of disease to effective prevention and treatment 3 . Although the aetiology of ovarian cancer has not been fully elucidated, it is generally agreed that family history of ovarian or breast cancer is the most important risk factor for epithelial ovarian cancer 4 . Hereditary ovarian cancers occurring in breast/ovarian cancer families have been linked to mutations in the BRCA1 and BRCA2 genes, while cases occurring in association with Lynch syndrome have been linked to mutations in MSH2 and MLH1 5, 6 . Given that only 3-5% of cases present as high-risk familial cases 3 , it is plausible that several lowpenetrance genes with relatively common alleles may account for a portion of the increased risk.
Fibroblast growth factor (FGF)-2 (basic) has been localized to 4q26-q27 and is a member of a large family of structurally related proteins that affect the growth and differentiation, migration and survival of a wide variety of cell types. It is highly conserved among eukaryotes with sequence homology of >90% across a wide range of species 7 . FGF2 is a potent angiogenic molecule and has been shown to induce migration and proliferation of endothelial cells which differentiate into new vascular structures 8 . Inactivation of FGF2 in vivo has been shown to suppress tumor growth through the inhibition of FGF2-induced angiogenesis 9 . Elevated levels of urinary FGF2 were shown to correlate significantly with metastatic disease in a wide range of cancers including ovarian tumors 10 . Expression studies in ovarian cancer cell lines have also demonstrated significant increases in mRNA expression of the FGF2 receptor, as well as dose-dependent increased cell numbers in response to exogenous stimulation by FGF2 11 . In addition, gene expression profiling of advanced ovarian tumors indicates that FGF2 signalling plays a central role throughout the carcinogenesis process 12 .
We hypothesised that common single nucleotide polymorphisms (SNPs) in the FGF2 gene may alter the angiogenic potential of FGF2 and thereby susceptibility to ovarian cancer. While there is much evidence that FGF2 is functionally relevant to tumor development and metastasis, to the best of our knowledge no study to date has assessed common variations in this gene for a possible association with ovarian cancer susceptibility. The current study evaluates twenty-five FGF2 SNPs for an association with ovarian cancer risk, and represents a collaborative effort using data from five case-control studies from the United States and Australia, all participants in the Ovarian Cancer Association Consortium (OCAC) 13 . OCAC is an international collaboration established to provide a forum for researchers to evaluate genetic associations with ovarian cancer with increased power.
Material and methods
Study Population
Details of study design, and case and control ascertainment for each study included in this analysis are summarized in Table 1 . A total of five ovarian cancer case-control studies contributed data to this analysis, four of which used population-based ascertainment methods and one (MAYO) that was clinic-based (Table 1) . Individuals with missing data on tumor behaviour, histology or race, and controls with prior oophorectomies, were excluded from the analysis. The final combined dataset comprised 1457 serous invasive cases and 3137 controls, the majority of whom were reported to be non-Hispanic Whites. All studies have been previously described elsewhere [14] [15] [16] [17] [18] . Approval from respective human research ethics committees was obtained, and all participants provided written informed consent.
Single Nucleotide Polymorphism Selection and Genotyping
Genotype data for this analysis was obtained from two 1536-SNP Illimina Golden Gate Assays™ conducted at two OCAC centers: AOCS-ACS and MAYO samples were genotyped at the Queensland Institute of Medical Research (QIMR), Queensland, Australia; DOVE, HOPE and USC samples were genotyped at the University of Southern California (USC) Epigenome Center, California, USA. Genotyping was conducted according to customized GoldenGate genotyping procedures (Illumina Inc.).
At QIMR we examined genotypes within 5 kb of FGF2 (June 2006) from the projects of the HapMap Consortium 19 , Perlegen 20 , NIEHS SNPs, and SeattleSNPs {http://pga.mbt.washington.edu/} and found HapMap to be the most informative for European-American samples using the binning algorithm of ldSelect 21 to identify tagging SNPs (tgSNPs) for SNPs with r 2 > 0.8 and minor allele frequencies (MAFs) > 0.05. Fifty-eight SNPs were sorted into 20 bins, yielding 20 tgSNPs, 2 of which failed assay conversion. At USC we selected tgSNPs for FGF2 (including putative regulatory regions 20kb up and 10kb downstream of the gene) using the program SNAGGER 22 . We attempted to tag all SNPs in HapMap (Release #21 July 2006) in the CEU population with a MAF of 0.05 or greater with an r 2 > 0.8.
A total of 25 FGF2 SNPs were selected across both collaborations, 17 of which were genotyped for all studies, one was genotyped for the AOCS-ACS and MAYO studies only and seven were genotyped for DOVE, HOPE and UCS studies only ( Table 2 ). The performance of our selected tgSNPs in capturing known common variation across the FGF2 gene was evaluated using Tagger 23 implemented in Haploview 24 . We estimate that 97% of the known common variants (MAF ≥ 0.05) across the FGF2 locus (including 20kb 5' and 10 kb 3' of the gene) have been captured by these SNPs.
Samples with call rates below 95% (or 90%), and SNPs with call rates below 98% (or 95%), were excluded at QIMR (and USC). At QIMR, SNPs with GenTrain scores < 0.5 were manually checked and adjusted according to Illumina guidelines; all SNPs were manually checked at USC. Greater than 97% and 93% at of SNPs passed this initial quality assurance at QIMR and USC respectively. Two samples per 96 well plate were blindly duplicated (n=20). One inter-and one intra-plate duplicate samples were included on each plate to assist with genotype calling and ensuring against plate flips. In addition, 128 blinded duplicate samples were included at USC. Genotyping quality was also assessed using tests for Hardy-Weinberg equilibrium (HWE). SNPs with significant deviations from HWE in controls (0.001<P<0.05) were assessed and the genotype data was excluded if the clustering was found to be suboptimal. SNPs with HWE P<0.001 were excluded from the analysis. Overall, >84% and 91% of SNPs passed all quality assurance criteria at QIMR and USC, respectively.
Statistical Analysis
Case-control analyses were restricted to White non-Hispanic women with serous invasive ovarian tumours. White women participating in Australian studies were assumed to be non-Hispanic. Genotype frequencies in non-Hispanic White controls for each FGF2 SNP were assessed for departure from HWE using the χ 2 goodness-offit test. Each of the five contributing case-control studies was assessed for differences in age at interview among controls and age at diagnosis among cases using Student's t-test for comparison of means. The MAF for each SNP was estimated from the control population for each study.
The combined odds ratios (ORs) and their 95% confidence intervals (95% CIs) were obtained from unconditional logistic regression models. Assuming a log additive model of inheritance, the per-allele risks associated with serous invasive tumors among non-Hispanic Whites for each of the 25 FGF2 SNP were estimated by fitting the number of rare alleles carried as a continuous covariate. All estimates were adjusted for study site, and age at diagnosis for cases or age at interview for controls. All tests for association were two-tailed and statistical significance was assessed at p<0.05 using STATA v. 9.0 (StataCorp, USA).
Results
Details of study design, and case and control ascertainment for each contributing study are summarized in Table 1 . Genotype data across the different studies met the minimum quality assurance measure for inclusion in the analysis, with the exception of rs17473132 SNP which was out of HWE in the USC study (p=0.0002), resulting in the exclusion of 374 genotypes for this SNP from the final dataset. Cases were significantly more likely to be older than controls (p <0.0001), and ranged in age at diagnosis from 23.6 to 86 years (mean age 60.1 ± 10.3) while controls ranged in age at interview from 19.2 to 91 years (mean age 56.9 ± 11.2; see Table 1 ).
Estimates for the 25 FGF2 SNPs and risk of invasive serous tumors were calculated among non-Hispanic White women, based on genotype data from a combined total of 1269 serous invasive cases and 2829 controls genotyped at both sites ( Table 2) . None of the 25 SNPs analysed were significantly associated with risk of ovarian cancer although, without correcting for multiple testing, two SNPs showed borderline evidence of an association. The per-allele estimate for the rs308447 SNP showed a borderline significant inverse association with serous tumors [OR per-allele = 0.87 (0.76 -1.00), p = 0.04]. However, although the heterozygous estimate supports an association [OR Het = 0.72 (0.59 -0.87) p = 0.001], the odds ratio for rare homozygotes was neither statistically significant (p>0.4) nor consistent with the log additive model of inheritance. Similarly the rs308379 SNP was inversely associated with serous tumors among heterozygotes [OR Het = 0.85 (0.74 -0.98) p = 0.03] but no equivalent association was observed among rare homozygotes (p= 0.59), nor were the estimates consistent with the log additive model of inheritance (Table 2 ). These observations are likely to be due to chance alone, and we therefore conclude that there is no association between any of these 25 SNPs in FGF2 and risk of invasive serous ovarian cancer in non-Hispanic White women.
Discussion
FGF2 is a potent angiogenic molecule that has been shown to promote tumour cell mitosis and has been implicated in the differentiation of stromal and epithelial cells from a dormant to an invasive phenotype 25 . We have evaluated the effects of 25 SNPs in the FGF2 gene on the risk of invasive serous ovarian cancer in non-Hispanic White women enrolled in five case-control studies from the United States and Australia, and found no convincing evidence of an association of any FGF2 SNPs with serous ovarian tumors in our combined dataset. We acknowledge that the potential for variation in estimates is inherent in analyses involving samples from different countries, given the likelihood of differences in case-control selection criteria and population differences attributable to environmental factors or genetic background. However, all contributing studies included in our analysis selected controls from the same source population as cases, participants were predominantly non-Hispanic White (Table 1) , and indeed there was no evidence of heterogeneity between the studies (non-Hispanic Whites only) for any of the SNPs included in this analysis (P Heterogeneity ≥0.14).
The human FGF2 gene encompasses 71.53 kb of genomic sequences on chromosome 4. Using Hapmap SNP genotype frequency data for FGF2 SNPs, we estimated that the 25 SNPs presented in this report capture 97% of the known common variation (MAF ≥ 0.05) across the FGF2 locus at r 2 ≥ 0.8 for pairwise correlations. To the best of our knowledge, this is the first study to evaluate FGF2 SNPs in a large multi-center study. Based on the method of Purcell et al 26 we estimated that we had ≥80% power to detect ORs of 1.20 at an alpha of 0.05 for the 19 SNPs with MAFs ≥0.1 (Table 2) . However, we acknowledge that we had considerably less power to detect these effect sizes with the six SNPs with MAFs < 0.1.
Our study highlights the importance of consortium-based approaches to investigating putative genetic association in case-control analyses, particularly for low-risk genes that require large sample sizes to detect small SNP effects. We note that three SNPs, in addition to the rs308447, achieved the minimal level of significance of p≤0.05 in study-specific per-allele estimates (data not shown), but not in the combined analysis. If we had reported the results of these individual case-control studies, it may have led other groups to attempt replication but our combined analysis provides a more accurate assessment of these associations and reduces publication bias.
FGF2 has been the focus of a plethora of studies into human tumor biology and has important implications for cancer therapies and clinical outcomes. FGF2 is one of several fibroblast growth factor molecules that interact with various vascular endothelial growth factors and cell surface receptors that are known to play a role in tumor growth and angiogenesis 27, 28 . The correlation between angiogenesis and the extent of metastatic disease has been widely demonstrated in a large and diverse range of human cancers [29] [30] [31] including advanced stage ovarian carcinoma 32, 33 . Abnormally high concentrations of FGF2 have been found in the serum of patients with active metastatic cancers and have been shown to correlate significantly with extent of disease, clinical status and risk of future mortality 10 . These findings would support the assessment of FGF2 polymorphisms with regard to ovarian cancer survival and prognosis in future studies. To date several functional angiogenic gene SNPs have been studied in solid cancers with varying results derived from sample sizes that are too small to detect the modest effects anticipated from these low penetrance genes 34 . Large-scale epidemiologic studies of other genes involved in angiogenesis are therefore warranted to further enhance our understanding of tumor progression. This could lead to novel approaches to risk stratification or the use of anti-angiogenic treatment strategies, if angiogenic potential, and hence prognosis, can be predicted according to individual genotype. 1: Minor allele frequency estimated from control population 2: Sample sizes reflect differences in genotype data available for analysis and exclusions based on HWE threshold 3: Odds Ratios (ORs) are adjusted for study and age (at interview for controls; at diagnosis for cases). Reference genotypes for case-control comparisons are common homozygotes 4: Indicates SNPs genotyped for DOVE, HOPE and USC studies only 5: Indicates SNPs genotyped for AOCS-ACS study only
